Skip to main content
Mark Kieran, MD, Pediatric Hematology & Oncology, Boston, MA, Dana-Farber Cancer Institute

MarkWilliamKieranMD

Pediatric Hematology & Oncology Boston, MA

Pediatric Neuro-Oncology

Associate Professor of Pediatrics, Dana-Farber Cancer Institute

Dr. Kieran is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Kieran's full profile

Already have an account?

Education & Training

  • Children's Hospital/Boston Medical Center
    Children's Hospital/Boston Medical CenterFellowship, Pediatric Hematology/Oncology, 1992 - 1995
  • University of Calgary Faculty of Medicine
    University of Calgary Faculty of MedicineClass of 1986
  • University of Alberta
    University of AlbertaPh.D., Medicine (Immunology), 1983
  • McMaster University
    McMaster UniversityB.Sc., Biochemistry, 1980

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 1992 - 2026
  • PA State Medical License
    PA State Medical License 2019 - 2024
  • American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly, 2008-2015
  • Boston Magazine Castle Connolly, 2008-2015
  • America's Top Doctors for Cancer Castle Connolly, 2005-2015
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Immunophenotyping of Pediatric Brain Tumors: Correlating Immune Infiltrate with Histology, Mutational Load, and Survival and Assessing Clonal T Cell Response  
    Isaac H Solomon, Mark W Kieran, Gabriel K Griffin, Pratiti Bandopadhayay, Jerome Ritz, Ashley S Plant, Keith L Ligon, Glenn Dranoff, Journal of Neuro-Oncology
  • The role of the farnesyltransferase inhibitor lonafarnib in the treatment of progeria  
    Kieran MW, Gordon LB, Kleinman ME, Expert Opin Orphan Drugs, 1/1/2014
  • Inhibition of tumor angiogenesis by oral etoposide  
    Panigrahy D, Kaipainen A, Butterfield CE, Chaponis DM, Laforme AM, Folkman J, Kieran MW, Experimental and Therapeutic Medicine, 1/1/2010
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Abstracts/Posters

  • A feasibility and randomized phase II study of vorinostat, bevacizumab, or temozolomide during radiation followed by maintenance chemotherapy in newly-diagnosed pediat...
    Hoffman LM, Geller G, Leach J, Boue D, Drissi R, Chen L, Panandiker A, Chow L, Haas-Kogan D, Jogal S, Nelson M, Jakacki R, Kieran MW, Cohen K, Pollack I, Gajjar A, Fou..., SNO Pediatric Basic and Translational Meeting, San Diego, CA, 1/7/2015
  • Phase 1 study of dabrafenib in pediatric patients (pts) with relapsed or refractory BRAF V600E high- and low-grade gliomas (HGG, LGG), Langerhans cell histiocytosis (L...
    Kieran MW, Hargrave D, Cohen K, Aerts I, Dunkel IJ, Hummel TR, Jimenez I, Pearson A, Pratilas C, Whitlock J, Bouffet E, Shen V, Broniscer A, Bertozzi A-I, Sandberg J, ..., ASCO, Chicago, IL, 1/1/2015
  • Intravascular fasciitis-like proliferation characterizes pediatric pulmonary vein stenosis: clinicopathologic analysis of 213 samples.
    Kovach A, Magcalas P, Ireland C, McEnany K, Kieran M, Jenkins K, Baird C, Vargas SO, Pediatr Devel Pathol; Society for Pediatric Pathology, 1/1/2015
  • Join now to see all

Lectures

  • Efficacy and safety results from a phase I/IIa study of dabrafenib in pediatric patients with BRAF V600 mutant relapsed refractory low-grade glioma. 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
  • Cancer Biology Seminar Series 
    Boston, MA - 1/6/2015
  • BRAF in pediatric cancer. 
    Chicago, IL - 1/30/2014
  • Join now to see all

Other

Press Mentions

  • An Ounce of Prevention: Preoperative Management of Inflammation May Stave off Cancer Recurrences
    An Ounce of Prevention: Preoperative Management of Inflammation May Stave off Cancer RecurrencesOctober 17th, 2019
  • New Targeted Cancer Therapies Prove Successful When Chemo Does Not
    New Targeted Cancer Therapies Prove Successful When Chemo Does NotJanuary 8th, 2019
  • After a Child's Dire Diagnosis, Hope and Uncertainty at the Frontiers of Medicine
    After a Child's Dire Diagnosis, Hope and Uncertainty at the Frontiers of MedicineDecember 6th, 2018
  • Join now to see all

Grant Support

  • Phase II Trial Of Lonafarnib, Pravastatin And Zoledronic Acid In ProgeriaNational Heart, Lung, And Blood Institute2009–2010
  • Phase I Trial Of Temozolomide And 06-Benzylguanine In Pediatric Patients W/ RecuNational Center For Research Resources2004–2005
  • Xenogen'S Ivis 100 Imaging System: Tissue EngineeringNational Center For Research Resources2004
  • Xenogen'S Ivis 100 Imaging System: CardiovascularNational Center For Research Resources2004
  • Xenogen'S Ivis 100 Imaging System: CancerNational Center For Research Resources2004
  • Xenogen'S Ivis 100 Imaging SystemNational Center For Research Resources2004
  • Harvard Pediatric Brain Tumor CenterNational Cancer Institute2000–2003
  • Pediatric Brain Tumor CenterNational Cancer Institute1999

Hospital Affiliations